Contribution of Cytochrome P450 and ABCB1 Genetic Variability on Methadone Pharmacokinetics, Dose Requirements, and Response

• Francina Fonseca,

  Affiliations Institut de Neuropsiquiatria i Addiccions - Parc de Salut Mar, Barcelona, Spain, Universitat Pompeu Fabra (CEXS-UPF), Barcelona, Spain, Disorders by Use of Substances Research Group, Neuropsychopharmacology Research Program, Institut Municipal d'Investigació Mèdica (IMIM-Hospital del Mar Research Institute), Barcelona, Spain

  ⨯
• Rafael de la Torre ,

  * E-mail: rtorre@imim.es (RdT); mtorrens@hospitaldelmar.cat (MT)

  Affiliations Universitat Pompeu Fabra (CEXS-UPF), Barcelona, Spain, Human Pharmacology and Clinical Neurosciences Research Group, Neuropsychopharmacology Research Program, Institut Municipal d'Investigació Mèdica (IMIM-Hospital del Mar Research Institute), Barcelona, Spain, CIBER de Fisiopatología de la Obesidad y Nutrición (CB06/03), Hospital Clínico Universitario Santiago de Compostela, Santiago de Compostela, Spain

  ⨯
• Laura Díaz,

  Affiliations Institut de Neuropsiquiatria i Addiccions - Parc de Salut Mar, Barcelona, Spain, Disorders by Use of Substances Research Group, Neuropsychopharmacology Research Program, Institut Municipal d'Investigació Mèdica (IMIM-Hospital del Mar Research Institute), Barcelona, Spain

  ⨯
• Antonio Pastor,

  Affiliations Human Pharmacology and Clinical Neurosciences Research Group, Neuropsychopharmacology Research Program, Institut Municipal d'Investigació Mèdica (IMIM-Hospital del Mar Research Institute), Barcelona, Spain, Pharmacology Department, Autonomous University of Barcelona, Barcelona, Spain

  ⨯
• Elisabet Cuyàs,

  Affiliations Human Pharmacology and Clinical Neurosciences Research Group, Neuropsychopharmacology Research Program, Institut Municipal d'Investigació Mèdica (IMIM-Hospital del Mar Research Institute), Barcelona, Spain, Pharmacology Department, Autonomous University of Barcelona, Barcelona, Spain

  ⨯
• Nieves Pizarro,

  Affiliations Human Pharmacology and Clinical Neurosciences Research Group, Neuropsychopharmacology Research Program, Institut Municipal d'Investigació Mèdica (IMIM-Hospital del Mar Research Institute), Barcelona, Spain, Pharmacology Department, Autonomous University of Barcelona, Barcelona, Spain

  ⨯
• Olha Khymenets,

  Affiliations Human Pharmacology and Clinical Neurosciences Research Group, Neuropsychopharmacology Research Program, Institut Municipal d'Investigació Mèdica (IMIM-Hospital del Mar Research Institute), Barcelona, Spain, CIBER de Fisiopatología de la Obesidad y Nutrición (CB06/03), Hospital Clínico Universitario Santiago de Compostela, Santiago de Compostela, Spain

  ⨯
• Magí Farré,

  Affiliations Human Pharmacology and Clinical Neurosciences Research Group, Neuropsychopharmacology Research Program, Institut Municipal d'Investigació Mèdica (IMIM-Hospital del Mar Research Institute), Barcelona, Spain, Pharmacology Department, Autonomous University of Barcelona, Barcelona, Spain

  ⨯
• Marta Torrens

  * E-mail: rtorre@imim.es (RdT); mtorrens@hospitaldelmar.cat (MT)

  Affiliations Institut de Neuropsiquiatria i Addiccions - Parc de Salut Mar, Barcelona, Spain, Disorders by Use of Substances Research Group, Neuropsychopharmacology Research Program, Institut Municipal d'Investigació Mèdica (IMIM-Hospital del Mar Research Institute), Barcelona, Spain, Psychiatric Department, Autonomous University of Barcelona, Barcelona, Spain

  ⨯